Bactiguard Holding AB (Bactiguard) (STO:BACTIB),a medical device company, announced on Friday that it has entered into an exclusive, global license agreement for orthopaedic trauma implants with Zimmer Biomet.

This agreement includes an upfront license fee of USD3m payable at signing, additional contingent payments of USD2m, based on US regulatory clearance and royalties on net sales following commercialisation.

According to the company, its new, global partnership has the potential of expanding Bactiguard's current license business significantly and making a substantial contribution to its license revenues, both in the near term and in a longer perspective.

Also, the Bactiguard technology is now approved for use in the urinary tract, respiratory tract, bloodstream and on orthopaedic implants. These metal implants are intended to stay in the body for many months, up to several years and sometimes lifelong and the regulatory approval clearly shows that the technology is safe for patients.

Orthopaedic trauma implants with Bactiguard's infection preventive technology were CE marked in December 2018 and will be used as a reference in the process of obtaining regulatory clearance.